2023 ACCP Virtual Journal Club Webinar: Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis | ON DEMAND

On Demand webinar recording: August 16th, 2023 to August 16th, 2026

Why is this article important to your practice? 

Venetoclax is an approved BCL-2 inhibitor that is primarily metabolized by cytochrome P450 3A (CYP3A). Although venetoclax exposure has been well characterized with one concomitant CYP3A inhibitor, complex drug-drug interactions involving more than one inhibitor have not been systematically evaluated despite the common polypharmacy in the target populations. In this webinar, the author will leverage physiologically-based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modeling to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics. The modeling approaches were informed by clinical data in the presence of single or multiple CYP3A inhibitors and the effects of one or more inhibitors were systematically evaluated within these modeling frameworks. Learners that complete this activity will be able to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics using PBPK and population PK modeling.

Target Audience:

Physicians, Pharmacists, PhDs and other healthcare professionals interested in PBPK/PopPK modeling, drug-drug interactions.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the rationale to assess and quantify the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics;
2. Describe the approaches and validation procedures used to inform dose adjustment for co-administration of venetoclax with multiple CYP3A inhibitors;
3. Describe the benefits and limitations of these approaches to identify the potential impact of multiple concomitant medications in the development of new agents.